Vincerx Pharma, Inc. (VINC)

0.8892 +0.0622 (+7.52%) At close: 04:00PM EDT

Vincerx Pharma, Inc.

260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676
https://vincerx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 42

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ahmed M. Hamdy M.D.	Co-Founder, Chairman & CEO	657.54k	N/A	1965
Dr. Raquel E. Izumi Ph.D.	Co-Founder, President, COO, Secretary & Director	591.54k	N/A	1970
Mr. Alexander A. Seelenberger M.B.A.	Chief Financial Officer	491.69k	N/A	1979
Mr. Tom C. Thomas J.D.	Founder, General Counsel & Chief Legal Officer	444.14k	N/A	1960
Dr. John C. Byrd M.D.	Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Hans-Georg Lerchen Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Gabriela Jairala	Sr Executive Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Karen Quarford	Vice President of Quality Operations & Compliance	N/A	N/A	N/A
Ms. Melissa Merrick SPHR	Senior Director of People & Culture and Head of Human Resource	N/A	N/A	N/A
Dr. Beatrix Stelte-Ludwig Ph.D.	Executive Chief Development Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Corporate governance

Vincerx Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.